BACKGROUND AND PURPOSE: The present study investigated whether the pathophysiological changes induced by burn and smoke inhalation are modulated by parenteral administration of Na(2)S, a H(2)S donor. EXPERIMENTAL APPROACH: The study used a total of 16 chronically instrumented, adult female sheep. Na(2)S was administered 1 h post injury, as a bolus injection at a dose of 0.5 mg.kg(-1) and subsequently, as a continuous infusion at a rate of 0.2 mg.kg(-1).h(-1) for 24 h. Cardiopulmonary variables (mean arterial and pulmonary arterial blood pressure, cardiac output, ventricular stroke work index, vascular resistance) and arterial and mixed venous blood gases were measured. Lung wet-to-dry ratio and myeloperoxidase content and protein oxidation and nitration were also measured. In addition, lung inducible nitric oxide synthase expression and cytochrome c were measured in lung homogenates via Western blotting and enzyme-linked immunosorbent assay (elisa) respectively. KEY RESULTS: The H(2)S donor decreased mortality during the 96 h experimental period, improved pulmonary gas exchange and lowered further increase in inspiratory pressure and fluid accumulation associated with burn- and smoke-induced acute lung injury. Further, the H(2)S donor treatment reduced the presence of protein oxidation and 3-nitrotyrosine formation following burn and smoke inhalation injury. CONCLUSIONS AND IMPLICATIONS: Parenteral administration of the H(2)S donor ameliorated the pulmonary pathophysiological changes associated with burn- and smoke-induced acute lung injury. Based on the effect of H(2)S observed in this clinically relevant model of disease, we propose that treatment with H(2)S or its donors may represent a potential therapeutic strategy in managing patients with acute lung injury.
BACKGROUND AND PURPOSE: The present study investigated whether the pathophysiological changes induced by burn and smoke inhalation are modulated by parenteral administration of Na(2)S, a H(2)Sdonor. EXPERIMENTAL APPROACH: The study used a total of 16 chronically instrumented, adult female sheep. Na(2)S was administered 1 h post injury, as a bolus injection at a dose of 0.5 mg.kg(-1) and subsequently, as a continuous infusion at a rate of 0.2 mg.kg(-1).h(-1) for 24 h. Cardiopulmonary variables (mean arterial and pulmonary arterial blood pressure, cardiac output, ventricular stroke work index, vascular resistance) and arterial and mixed venous blood gases were measured. Lung wet-to-dry ratio and myeloperoxidase content and protein oxidation and nitration were also measured. In addition, lung inducible nitric oxide synthase expression and cytochrome c were measured in lung homogenates via Western blotting and enzyme-linked immunosorbent assay (elisa) respectively. KEY RESULTS: The H(2)Sdonor decreased mortality during the 96 h experimental period, improved pulmonary gas exchange and lowered further increase in inspiratory pressure and fluid accumulation associated with burn- and smoke-induced acute lung injury. Further, the H(2)Sdonor treatment reduced the presence of protein oxidation and 3-nitrotyrosine formation following burn and smoke inhalation injury. CONCLUSIONS AND IMPLICATIONS: Parenteral administration of the H(2)Sdonor ameliorated the pulmonary pathophysiological changes associated with burn- and smoke-induced acute lung injury. Based on the effect of H(2)S observed in this clinically relevant model of disease, we propose that treatment with H(2)S or its donors may represent a potential therapeutic strategy in managing patients with acute lung injury.
Authors: Lina Du; Xiaopeng Zhang; Yong Y Han; Nancy A Burke; Patrick M Kochanek; Simon C Watkins; Steven H Graham; Joseph A Carcillo; Csaba Szabó; Robert S B Clark Journal: J Biol Chem Date: 2003-03-07 Impact factor: 5.157
Authors: George D Webb; Lay Har Lim; Vernon M S Oh; Soh Bee Yeo; Yoke Ping Cheong; Muhammed Yusuf Ali; Reida El Oakley; Chuen Neng Lee; Poo Sing Wong; Michael G Caleb; Manuel Salto-Tellez; Madhav Bhatia; Edwin S Y Chan; Elizabeth A Taylor; Philip K Moore Journal: J Pharmacol Exp Ther Date: 2007-11-20 Impact factor: 4.030
Authors: Robert A Cox; Ann S Burke; Sam Jacob; Gloria Oliveras; Kazunori Murakami; Katsumi Shimoda; Perenlei Enkhbaatar; Lillian D Traber; David N Herndon; Daniel L Traber; Hal K Hawkins Journal: J Burn Care Res Date: 2009 May-Jun Impact factor: 1.845
Authors: Neel R Sodha; Richard T Clements; Jun Feng; Yuhong Liu; Cesario Bianchi; Eszter M Horvath; Csaba Szabo; Frank W Sellke Journal: Eur J Cardiothorac Surg Date: 2008-03-07 Impact factor: 4.191
Authors: Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah Journal: J Surg Res Date: 2012-06-27 Impact factor: 2.192
Authors: Katalin Módis; Eelke M Bos; Enrico Calzia; Harry van Goor; Ciro Coletta; Andreas Papapetropoulos; Mark R Hellmich; Peter Radermacher; Frédéric Bouillaud; Csaba Szabo Journal: Br J Pharmacol Date: 2014-04 Impact factor: 8.739
Authors: Oscar McCook; Peter Radermacher; Chiara Volani; Pierre Asfar; Anita Ignatius; Julia Kemmler; Peter Möller; Csaba Szabó; Matthew Whiteman; Mark E Wood; Rui Wang; Michael Georgieff; Ulrich Wachter Journal: Nitric Oxide Date: 2014-03-18 Impact factor: 4.427
Authors: Alisa M Agné; Jan-Peter Baldin; Audra R Benjamin; Maria C Orogo-Wenn; Lukas Wichmann; Kenneth R Olson; Dafydd V Walters; Mike Althaus Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-01-28 Impact factor: 3.619
Authors: Edward A Wintner; Thomas L Deckwerth; William Langston; Asa Bengtsson; Dina Leviten; Paul Hill; Michael A Insko; Ronald Dumpit; Emily VandenEkart; Christopher F Toombs; Csaba Szabo Journal: Br J Pharmacol Date: 2010-06 Impact factor: 8.739
Authors: Christopher F Toombs; Michael A Insko; Edward A Wintner; Thomas L Deckwerth; Helen Usansky; Khurram Jamil; Brahm Goldstein; Michael Cooreman; Csaba Szabo Journal: Br J Clin Pharmacol Date: 2010-06 Impact factor: 4.335